Solid Biosciences Gets FDA IND, Health Canada CTA Nod for First-In-Class Cardiac Gene Therapy CPVT
ReutersJul 8, 2025 9:28 PM
July 8 (Reuters) - Solid Biosciences Inc SLDB.O:
SOLID BIOSCIENCES ANNOUNCES FDA IND AND HEALTH CANADA CTA APPROVAL FOR FIRST-IN-CLASS CARDIAC GENE THERAPY TO TREAT CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)
SOLID BIOSCIENCES INC - EXPECTS TO INITIATE PHASE 1B CLINICAL TRIAL OF SGT-501 IN Q4 OF 2025
SOLID BIOSCIENCES INC - PHASE 1B CLINICAL TRIAL FOR SGT-501 EXPECTED IN Q4 2025
SOLID BIOSCIENCES- EXPANDS SOLID'S CLINICAL PIPELINE TO INCLUDE FIRST CARDIAC INDICATION WITH URGENT UNMET MEDICAL NEED
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
[Reuters Analysis] Trump's antitrust enforcers 'get out of the way' of multibillion-dollar deals
July 10 (Reuters) - President Donald Trump's antitrust enforcers recently cleared a string of multibillion-dollar deals in a week, demonstrating a willingness to settle with companies that marks a shift from the Biden administration.Reuters
19 minutes ago
[Reuters Analysis] Brazil has few exit routes from Trump tariff but feels less pain
BRASILIA, July 10 (Reuters) - When U.S. President Donald Trump linked 50% tariffs on Brazil to the trial against his ally, the country's former far-right leader, Washington left Latin America's largest economy with few options to deescalate but may have overestimated the country's vulnerability to tReuters
19 minutes ago
Q2 2025 Earnings Season Preview: The First Test Under Trump’s Tariffs — Could Low Expectations Bring Surprises?
TradingKey - Mid-July will mark the first earnings season since President Donald Trump’s tariff policy took effect, offering investors a glimpse into how American companies are handling the impact of trade tensions. Analysts believe that with low expectations heading into Q2, it may be easier forTradingKey
Wed, Jul 9
Japan: Yen Likely to Rise or Stabilise, Unlikely to Fall, with High Odds for Bulls
TradingKey - We anticipate a high likelihood of the Japanese yen appreciating in the short term (0-3 months). This outlook is driven by two key factors: First, the diverging monetary policies of the U.S. and Japan (Federal Reserve rate cuts paired with Bank of Japan rate hikes) will support the...TradingKey
Mon, Jul 7
Prediction! Federal Reserve Chairman Jerome Powell's Next Move Will Be an Interest Rate Cut
The Federal Reserve must balance the risks of higher inflation with the risks of higher unemployment when making decisions on interest rates.Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »*Stock prices used were..The Motley Fool
Thu, Jun 26
Tradingkey
